Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure
Michael Szarek, Deepak L. Bhatt, Philippe Gabríel Steg, et al.
Annals of Internal Medicine (2021) Vol. 174, Iss. 8, pp. 1065-1072
Open Access | Times Cited: 63

Showing 1-25 of 63 citing articles:

Kidney and heart failure outcomes associated with SGLT2 inhibitor use
Annemarie B. van der Aart‐van der Beek, Rudolf A. de Boer, Hiddo J.L. Heerspink
Nature Reviews Nephrology (2022) Vol. 18, Iss. 5, pp. 294-306
Open Access | Times Cited: 115
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial
Rahul Aggarwal, Deepak L. Bhatt, Michael Szarek, et al.
The Lancet Diabetes & Endocrinology (2025)
Closed Access | Times Cited: 5
Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events
Bertram Pitt, Deepak L. Bhatt, Michael Szarek, et al.
JACC Heart Failure (2023) Vol. 11, Iss. 8, pp. 879-889
Open Access | Times Cited: 26
Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis
Rami Aldafas, Thomas Crabtree, Mohammed Alkharaiji, et al.
Age and Ageing (2024) Vol. 53, Iss. 1
Open Access | Times Cited: 16
Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes
P. Natale, David J. Tunnicliffe, Tadashi Toyama, et al.
Cochrane library (2024) Vol. 2024, Iss. 5
Closed Access | Times Cited: 11
Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD
Vikas S. Sridhar, Deepak L. Bhatt, Ayodele Odutayo, et al.
Clinical Journal of the American Society of Nephrology (2024) Vol. 19, Iss. 5, pp. 557-564
Open Access | Times Cited: 10
Systematic review of sodium‐glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure‐related events
Buena Aziri, Edin Begić, Slobodan Јаnkovic, et al.
ESC Heart Failure (2023) Vol. 10, Iss. 3, pp. 1499-1530
Open Access | Times Cited: 23
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial
Meir Schechter, Stephen D. Wiviott, Itamar Raz, et al.
The Lancet Diabetes & Endocrinology (2023) Vol. 11, Iss. 4, pp. 233-241
Open Access | Times Cited: 16
Recurrent Events in Cardiovascular Trials
John Gregson, Gregg W. Stone, Deepak L. Bhatt, et al.
Journal of the American College of Cardiology (2023) Vol. 82, Iss. 14, pp. 1445-1463
Open Access | Times Cited: 15
The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus
Bertram Pitt, Philippe Gabríel Steg, Lawrence A. Leiter, et al.
Cardiovascular Drugs and Therapy (2021) Vol. 36, Iss. 3, pp. 561-567
Open Access | Times Cited: 31
Inpatient diabetes management
Andrew P. Demidowich, Camille Stanback, Mihail Zilbermint
Annals of the New York Academy of Sciences (2024) Vol. 1538, Iss. 1, pp. 5-20
Closed Access | Times Cited: 4
Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial
Kim A. Connelly, C. David Mazer, Pankaj Puar, et al.
Circulation (2022) Vol. 147, Iss. 4, pp. 284-295
Open Access | Times Cited: 19
Immediate and short-term outcomes of in-hospital canagliflozin initiation in acute heart failure: Results from the CANA-AHF randomized clinical trial
Rabab A. El-Gazar, Bassem Zarif, Ahmed Ali Ali, et al.
Heart & Lung (2025) Vol. 72, pp. 65-73
Closed Access
Incremental benefits of combined inhibition of SGLT1 and SGLT2 with sotagliflozin
Ram D. Bhatt, Bertram Pitt, Philippe Gabríel Steg, et al.
Progress in Cardiovascular Diseases (2025)
Closed Access
Sotagliflozin provides additional benefits for high-fat diet-induced cardiac inflammatory injury by extra inhibiting P38MAPK and JNK
Jian-Chao Luo, Le-hao Jin, Yun-Shan Zhong, et al.
International Immunopharmacology (2025) Vol. 155, pp. 114631-114631
Closed Access
Advances in cardiovascular pharmacotherapy. III. Sodium-glucose cotransport type 2 inhibitors, part 1: efficacy in heart failure and myocardial infarction
Paul S. Pagel, Dustin Hang, Julie K. Freed, et al.
Journal of Cardiothoracic and Vascular Anesthesia (2025)
Closed Access
Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review
Shaline Rao
Advances in Therapy (2021) Vol. 39, Iss. 2, pp. 845-861
Open Access | Times Cited: 23
Sotagliflozin attenuates liver associated disorders in cystic fibrosis rabbits
Xiubin Liang, Xia Hou, Mohamad Bouhamdan, et al.
JCI Insight (2024)
Open Access | Times Cited: 3
Heart failure with mildly reduced and preserved ejection fraction: A review of disease burden and remaining unmet medical needs within a new treatment landscape
Nihar R. Desai, Elżbieta Olewińska, Agata Famulska, et al.
Heart Failure Reviews (2024) Vol. 29, Iss. 3, pp. 631-662
Open Access | Times Cited: 3
A Review of Sotagliflozin: The First Dual SGLT-1/2 Inhibitor
Zoya Siddiqui, Niloofar Rasouli, Eliana Felder, et al.
Cardiology in Review (2024)
Closed Access | Times Cited: 3
Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure
Ankeet S. Bhatt, Deepak L. Bhatt, Philippe Gabríel Steg, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 12, pp. 1078-1088
Open Access | Times Cited: 3
Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease
Meir Schechter, Niels Jongs, Glenn M. Chertow, et al.
Annals of Internal Medicine (2022) Vol. 176, Iss. 1, pp. 59-66
Open Access | Times Cited: 13
The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non‐Asian populations of the EMPA‐REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease
Kohei Kaku, Christoph Wanner, Stefan D. Anker, et al.
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. 4, pp. 662-674
Open Access | Times Cited: 17
Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial
Toru Kondo, Ulrik M. Mogensen, Atefeh Talebi, et al.
Journal of the American College of Cardiology (2024) Vol. 83, Iss. 20, pp. 1973-1986
Open Access | Times Cited: 2
Cost-Effectiveness of Sotagliflozin in SOLOIST-WHF
William S. Weintraub, Paul Kolm, Sarahfaye Dolman, et al.
JACC Heart Failure (2024) Vol. 12, Iss. 9, pp. 1600-1610
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top